Search
Lung_Cancer_Backgrounder.pdf
Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
Option to Acquire Trutino Biosciences
Option to Acquire Trutino Biosciences
Clinical Collaborations
Clinical Collaborations
Women in STEM: Passion for science
Discover how our women excelling in STEM careers can improve health equity and create sustainable healthcare solutions.
VSV-GP
VSV-GP
Veterinary oncology experts meet in Germany
Veterinary oncology experts meet prior to the European Society of Veterinary Oncology Congress in Hofheim, Germany
Boehringer Ingelheim partners with PetMedix
Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
Genomic Lens Linking Worlds in DNA
Adding a new dimension to drug discovery with the help of data science and DNA
Boehringer Olaf Scholz break ground for innovation center
Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
CD137/FAP agonist
CD137/FAP agonist
Odile Bain Memorial Prize 2021
Brilliant early-career scientists in parasitology recognized
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager: DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
Advance study vaccinating increased milk production
[New ADVANCE study shows vaccinating with Bovela® results in increased milk production
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
Rethinking mental health care
Outdated perceptions and practices fuelling mental health crisis, new Economist Impact study reveals
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
Covid Global Support Programm
COVID-19: Boehringer Ingelheim steps up effort with Global Support Program
New Partnership to Develop Gene Therapy for Cystic Fibrosis
Boehringer Ingelheim steps into the field of gene therapy with experienced partners to jointly develop first gene therapy for cystic fibrosis
Vargatef®
Combination therapy with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.
Dr. Hsing-Jung Chen-Engerer
Prioritizing development with Dr. Hsing-Jung Chen-Engerer